InvestorsHub Logo
Followers 4
Posts 962
Boards Moderated 0
Alias Born 04/28/2013

Re: Insync_2000 post# 158016

Monday, 11/12/2018 5:39:17 PM

Monday, November 12, 2018 5:39:17 PM

Post# of 426487

Supposedly it was done under an NDA prior to the release of the results and if that is the case, what the hell was John Thero thinking. Talk about shooting yourself in the foot.



PR is a double-edged sword. The standard operating procedure in getting articles around a big event is to embargo information through NDAs, and send it to any credentialled journalist asking for it. I imagine there's a stricter protocol when dealing with SEC regs, AHA agreements, etc, but journalists don't get a second pass at breaking an NDA.

SOme have questioned how Nissen could be interviewed about a study he hadn't seen; I expect that Herper and Feuerstein gave snippets verbally for Nissen and others quoted to give feedback on. Again, this would not be unusual. What is noteworthy is that Nissen is heading a competing trial, but that was noted in the article. Still, that edges an ethical line.

In the end, disappointing that what's really a non-issue has the legs it has today. I don't blame Thero in the least for any of this; I think he's done a great job overall. Many of us are being typical Americans, wanting instant gratification. Plus, in my case, my side hustle of playing options had been going swimmingly and I was starting to think I was smart, lol.

Price held up well today; it may even rise over the course of the week--though someone on ST noted that max pain this week is $18... Hang in there, folks. Long term great company and product. Maybe an unexpected chance to acquire more.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News